The October 30th FDA advisory committee meeting convened to discuss our portfolio company Sydnexis’s pediatric myopia treatment SYD-101 had me questioning my sanity and left me worried for the future of innovation in this space. I had to write about it.
racap.com/rapport/sydnexis-f…
Zach Scheiner retweeted
pretty nuts that the total US annual spend on every single cancer drug combined is less than just OpenAI + Anthropic’s coding agent ARR
Thank you TJ, well done.
The year is 1854. Cholera is killing thousands in London. John Snow traces an outbreak to a contaminated water pump. Everyone blames bad air. Eventually cities separate sewage from drinking water. Clean water and sanitation will save more lives than almost anything medicine invents.
The year is 1867. Surgery is often more dangerous than the disease it treats. Joseph Lister starts cleaning instruments and wounds with antiseptic. Other surgeons ridicule him. Infections plummet.
The year is 1890. Your daughter has diphtheria. A thick membrane is forming in her throat, slowly suffocating her. The doctor injects a new antitoxin. She survives. A disease that killed tens of thousands of children will become almost unheard of in America.
The year is 1922. Your 14-year-old son has diabetes. He is starving to death no matter how much he eats. The only treatment is a starvation diet. The doctor injects insulin. His blood sugar falls. Children who would have died within months will grow up and have children.
The year is 1943. Your daughter has pneumonia. Before antibiotics, doctors could do little but hope. Now they give her penicillin. The fever breaks. Infections that routinely killed healthy adults become treatable.
The year is 1955. Parents are terrified of polio. Swimming pools close. Children become paralyzed. Some spend their lives in iron lungs. Jonas Salk develops a vaccine, tested in more than a million children. Within decades, polio disappears from America.
The year is 1960. Your wife is giving birth, and something goes wrong. A century earlier, she might have died. Now there are blood transfusions, antibiotics, safer cesarean sections, and anesthesia. Maternal mortality has fallen dramatically. Millions of women survive childbirth who otherwise wouldn’t have.
The year is 1978. Your blood pressure is 180 over 110. You feel fine. The doctor prescribes a pill. Clinical trials show that treating hypertension prevents strokes, heart failure, and death. You take it every morning. Nothing happens. That’s the point.
The year is 1980. The WHO declares smallpox eradicated. A disease that killed hundreds of millions in the twentieth century has disappeared from nature. Not treated. Not managed. Eliminated.
The year is 1996. Your brother has HIV. A decade earlier, the diagnosis was effectively a death sentence. Now doctors combine antiretroviral drugs. People who had months to live begin living for decades. Many will have near-normal life expectancies.
The year is 2014. Your father has hepatitis C. For decades, the infection has meant liver failure and cancer. Now he takes pills for twelve weeks. The virus disappears. A lifelong infection becomes curable in more than 95% of patients.
The year is 2019. Your daughter has cystic fibrosis. Her lungs are slowly failing. For decades, treatment meant managing infections and delaying the inevitable. Now doctors have a drug that corrects the underlying protein defect. Her breathing improves. Hospitalizations plummet. Predicted median survival rises from roughly 40 to more than 60 years.
The year is 2026. Your doctor has ten minutes and a screen. Your blood pressure is high, so the tablet is for life. Your cholesterol is high, so another tablet is for life. Your weight is high, so she offers an injection. The drugs have side effects. Not everyone needs them. But clinical trials show that appropriate treatment prevents heart attacks, strokes, kidney disease, and death.
None of these treatments is perfect. None needs to be.
For most of human history, parents buried their children, infections killed healthy adults, and childbirth killed young women.
Today, global life expectancy has more than doubled since 1900. Child mortality has collapsed.
Medicine has made terrible mistakes. We should remember them.
We should also remember the hundreds of millions of people alive because somebody got it right.
2
182
Zach Scheiner retweeted
The year is 1854. Cholera is killing thousands in London. John Snow traces an outbreak to a contaminated water pump. Everyone blames bad air. Eventually cities separate sewage from drinking water. Clean water and sanitation will save more lives than almost anything medicine invents.
The year is 1867. Surgery is often more dangerous than the disease it treats. Joseph Lister starts cleaning instruments and wounds with antiseptic. Other surgeons ridicule him. Infections plummet.
The year is 1890. Your daughter has diphtheria. A thick membrane is forming in her throat, slowly suffocating her. The doctor injects a new antitoxin. She survives. A disease that killed tens of thousands of children will become almost unheard of in America.
The year is 1922. Your 14-year-old son has diabetes. He is starving to death no matter how much he eats. The only treatment is a starvation diet. The doctor injects insulin. His blood sugar falls. Children who would have died within months will grow up and have children.
The year is 1943. Your daughter has pneumonia. Before antibiotics, doctors could do little but hope. Now they give her penicillin. The fever breaks. Infections that routinely killed healthy adults become treatable.
The year is 1955. Parents are terrified of polio. Swimming pools close. Children become paralyzed. Some spend their lives in iron lungs. Jonas Salk develops a vaccine, tested in more than a million children. Within decades, polio disappears from America.
The year is 1960. Your wife is giving birth, and something goes wrong. A century earlier, she might have died. Now there are blood transfusions, antibiotics, safer cesarean sections, and anesthesia. Maternal mortality has fallen dramatically. Millions of women survive childbirth who otherwise wouldn’t have.
The year is 1978. Your blood pressure is 180 over 110. You feel fine. The doctor prescribes a pill. Clinical trials show that treating hypertension prevents strokes, heart failure, and death. You take it every morning. Nothing happens. That’s the point.
The year is 1980. The WHO declares smallpox eradicated. A disease that killed hundreds of millions in the twentieth century has disappeared from nature. Not treated. Not managed. Eliminated.
The year is 1996. Your brother has HIV. A decade earlier, the diagnosis was effectively a death sentence. Now doctors combine antiretroviral drugs. People who had months to live begin living for decades. Many will have near-normal life expectancies.
The year is 2014. Your father has hepatitis C. For decades, the infection has meant liver failure and cancer. Now he takes pills for twelve weeks. The virus disappears. A lifelong infection becomes curable in more than 95% of patients.
The year is 2019. Your daughter has cystic fibrosis. Her lungs are slowly failing. For decades, treatment meant managing infections and delaying the inevitable. Now doctors have a drug that corrects the underlying protein defect. Her breathing improves. Hospitalizations plummet. Predicted median survival rises from roughly 40 to more than 60 years.
The year is 2026. Your doctor has ten minutes and a screen. Your blood pressure is high, so the tablet is for life. Your cholesterol is high, so another tablet is for life. Your weight is high, so she offers an injection. The drugs have side effects. Not everyone needs them. But clinical trials show that appropriate treatment prevents heart attacks, strokes, kidney disease, and death.
None of these treatments is perfect. None needs to be.
For most of human history, parents buried their children, infections killed healthy adults, and childbirth killed young women.
Today, global life expectancy has more than doubled since 1900. Child mortality has collapsed.
Medicine has made terrible mistakes. We should remember them.
We should also remember the hundreds of millions of people alive because somebody got it right.
The year is 1873. Your wife tires easily and reads too much. The doctor prescribes the rest cure: six weeks flat in bed, no books, no visitors, fed on milk, forbidden to sit up without his permission. The man who devised it is the most famous nerve specialist in America, and the women come out of it quieter, which is taken as the cure.
The year is 1915. The hospital has a new way of delivering your child. Morphine, then scopolamine, and the mother wakes two days later with a baby she cannot remember having. They call it twilight sleep. The women are strapped into padded cots so they do not hurt themselves while they scream, and the straps are the modern part. The babies arrive blue and slow to breathe.
The year is 1945. The truck comes down your street fogging DDT, and the children run behind it in the white cloud because the man on the back says it is harmless. At the beach it is sprayed over the bathers on their towels. It goes on the cattle, over the barn, and across the kitchen table.
The year is 1948. Your son has trouble with his ears. The doctor slides a rod tipped with radium up each nostril and holds it there for the best part of ten minutes, and you bring him back three more times. Hundreds of thousands of American children get the same treatment. The cancers arrive in their fifties.
The year is 1962. The health visitor tells you breastfeeding is old-fashioned and the formula is scientific. By 1972 fewer than one American baby in four is breastfed at all. The formula is skimmed milk and sugar, with the milk fat taken out and vegetable oil put in.
The year is 1971. The family planning clinic fits a small plastic crab called the Dalkon Shield. Its tail is a bundle of fibres that wicks bacteria up into the womb. 2.8 million are fitted in America before it is withdrawn, and the company goes bankrupt under the claims. It had been sold as safe and superior.
The year is 1983. The doctor says your arteries are the butter's fault. The dripping tin goes in the bin, the yolks go to the dog, the margarine goes in the fridge, and you have the heart attack anyway, on skimmed milk, having done everything right.
The year is 2001. Your 15-year-old is low, and the doctor prescribes Paxil, because the trial in the journal says it is effective and well tolerated in adolescents. The raw data, reanalysed 14 years later, shows more suicidal thinking on the drug than on the sugar pill. The company pays $3 billion to settle. Nobody rings the house.
The year is 2009. The government has spent around £500 million stockpiling Tamiflu for the pandemic, on the strength of the manufacturer's trials. When the trials are finally prised loose five years later, the drug shortens flu by about half a day and nothing shows it keeps anyone out of hospital. The stockpile goes out of date in a warehouse.
The year is 2026. The doctor has ten minutes and a screen. The number is high, so the tablet is for life. The weight is high, so the injection is for life. The meat is bad for the planet and the oil is good for the heart, and the person in the chair is as certain as everyone who ever sat in it.
Every one of those was settled, by a committee, in a journal, with a doubter somewhere being laughed at. The rest cure, the straps, the fog, the rod, the formula, the crab, the margarine, the trial, the stockpile. All of it certain, all of it printed, all of it done to somebody who had asked for help.
You were never the one who was wrong. You were the one it was done to, and the only person in the story who did as they were told every single time.
The apology comes a generation late, in a footnote, addressed to nobody.
The next one is being drafted now.
Zach Scheiner retweeted
Whom to blame? What to fix?
When there’s a downturn in development-stage biotech (ie must raise money), some companies feel it as a drop in valuation but some simply can’t raise money on any terms.
Some see that as a problem that needs blame and/or fixing. That some programs aren’t getting funding is unconscionable!
That’s good. I think it good that there are people who feel indignant that a world that funds so much luxury and entertainment can’t spare the money for their program, which they believe with all their heart is worthy. R&D needs its committed champions.
Don’t blame just the life science investors for not getting the value of a program. Blame all the savers of the world. That’s where the money comes from. Only a portion of it is allotted to life science investors.
But before we blame, consider an alternative model. There are essentially 3 sources of capital for development-stage biotech. Pharma, VC, and public markets. There are sub-categories of those but let’s stick with just three for now.
There once was a time when private companies had access to only two of those three: pharma and VC. And before 2010, VC was separate from public market capital. There was virtually no crossover capital. eg. RA Capital was a hedge fund.
So when the public markets crashed, strategics kept doing deals and VCs had their committed capital and would continue to fund private companies. VCs would no doubt look ahead to their probability of getting returns and exits and consider how likely they would be to raise the next fund. And if they were worried, they might slow their roll, making fewer new investments and stretching capital for existing companies. And so there were still entrepreneurs complaining that they couldn’t raise money.
The public funds would focus on public companies. To buy something, they could sell something, so the fittest survived. But their capital wasn’t committed and locked up, so LPs could withdraw money from biotech. Some companies could still access strategic capital.
Seeing lots of derisked companies drop in valuation make public investors less eager for IPOs of new companies. The window would be said to be “closed”. In reality, it just meant that sellers and buyers couldn’t agree on a price and didn’t want to transact. Effect was that privates stayed private and had to survive so harder for new companies to get new capital.
Whatever the macro conditions that caused the public markets to turn down tended to make it hard to raise a new VC fund. The world’s savers hunkered down and biotech had to work with what it had.
Keep in mind… there is and always has been far more life science capital on the public side than in VC funds available to private companies. That’s why as private companies reached later stages of development, they had to go public to access to bigger pools of capital (with very few exceptions, some involving strategic partnerships).
But once crossover investing became common, everything changed for private companies. Public funds could invest in private companies. Suddenly, the vast amounts of public capital could flow into private markets.
More ideas got funded.
But it now meant that the capital could be rapidly withheld when the public markets dropped. As capital flowed to undervalued public companies, money that was previously only withheld from IPO financings could now be withheld from Series A/B/C financings.
That’s painful for companies, but would those companies ever have come into existence if not for the advent of crossover investing?
So when crossover markets taketh away from privates, spare a thought for how much more they had giveth.
We wouldn’t want to go back to pre-crossover era. But current era require adaptability.
Side note: evolution of crossover investing forced a speciation of VC into crossover and formation fund. They had to choose because companies raising their private rounds preferred investors who wouldn’t treat the IPO as an exit.
Zach Scheiner retweeted
I think the biggest market pharma will ever tackle will actually be weight gain PREVENTION. And the dynamics of this market are going to be very different from the medicalized weight loss market and require better, more convenient products. The race for that market has only just begun.
We helped to pivot one of our companies, Terrestrial, to work in prevention (as well as weight loss), and their clinical progress now makes me comfortable sharing our thesis for the weight gain prevention space. They have a needle-free, room-temp stable microneedle patch where the microneedles are made of semaglutide. Apply it for a few min, the base of the needles dissolves leaving drug under the skin, and you can then throw away the patch. That’s the weekly dose. No sharps containers. Once drug is under skin, it behaves very similarly to regularly injected semaglutide.
505b2 path to market is derisked by all existing data on sema. But Terrestrial isn’t stopping at just getting approved for all same indications as sema. It’s also gunning to get it OTC and get weight gain prevention on the label, legitimizing what today is a common off-label use (so common that South Park parodied it).
From a societal value, there may not be any single medical breakthrough that rivals what a needle-free, OTC QW GLP-1 can offer to humanity. Excess weight leads to so much disability, disease, cost, lost productivity, and early mortality. Doesn’t make sense for people to have to gain weight to then get help losing it. Makes more sense for them to get help quieting the hunger noise (drive to eat) so they can avoid gaining weight in the first place.
Have doubts? No problem. Read the article and then decide.
The key insight here is that an OTC needle-free GLP-1 is not simply some late comer to a mature category but actually the beginning of an entirely new market that is so large that it would be worth any consumer-focused company to pay attention and for any standard pharma to consider what it would take to pivot into this space.
And if you have never experienced how a GLP-1 can quiet hunger noise, you’ll have a harder time relating. Young people with fast metabolisms will likely miss this. But someday they will say “holy crap, I get it!”.
60% of Americans are overweight or obese… the battle against weight gain is one most people are destined to lose without help. 3B people around the world are overweight/obese. This is a giant global market at even very low unit prices (eg $25/month).
Enjoy the read. Godspeed Terrestial! The RA Capital team is really proud to support you.
Zach Scheiner retweeted
Replying to @fle864
Hey Franck, I am actually arguing for the opposite..a more global industry - research, manufacturing and medicines reaching patients. But this requires developed countries to bear their share of the risk adjusted R&D costs for the newest treatments. EU the clear outlier here as the current practices are to delay access for as long as possible, reimburse only a subset of indicated and studied populations and then price reference less developed countries to drive post launch economics as low as possible for inventors. For 2-4% of the health care bill, or .3% of GDP, EU could be back in the game and keep an industry that is now walking out the door.
Zach Scheiner retweeted
For all the talk of Anthropic curing all diseases in 5-10 years, they could make an immediate timeline impact beyond anyone’s wildest dreams if they equipped biotech companies, research sites and CROs with their own legal agents that allowed them all to set their own parameters for a clinical trial agreement negotiation.
The gains would compound if they rinsed and repeated for every such bureaucratic hurdle in clinical development.
Zach Scheiner retweeted
On @MakingMedPod, @johnbstanford kicks off a new series, How America Makes Medicine. The series celebrates 250 years of American medical innovation, with Episode 1 exploring the most significant milestones in the history of medicine. youtube.com/watch?v=EMMGyp1y…
Zach Scheiner retweeted
Insurance companies must answer for deaths resulting from denial of coverage. Suicidal husband & father admitted to inpatient psych hospital then forcibly discharged against advice of physician/facility due to non coverage of insurance. He committed suicide shortly after. statnews.com/2026/07/20/psyc… @statnews
Zach Scheiner retweeted
A few people have asked me to comment on this article & the topic of US biotech competitiveness vis-à-vis China. I agree w/ Peter & Tess that expanding the COINS Act to biotech would have negative consequences. Risks handing global leadership & profits to EU competitors while doing little to slow China’s dominance. Also agree that we must protect critical supply chains/manufacturing from a national security perspective.
While COINS for biotech is a bad idea, we need proactive legislation to strengthen US biotech innovators. Targeted measures could include tradable/refundable R&D tax credits (noted in article) & priority review vouchers (@rtnarch), NOL reforms (amending Section 382), enhanced data exclusivity for genuine first-in-class assets & patent reform. These could level the playing field for US innovators without the protectionism & restrictions that would raise costs & slow patient access to new medicines
The paradox of biotech protectionism: Why walling off China biotech weakens America
US ban on Chinese biotech/trials would return pharma leadership to Europe, slow US patient access to new meds, & lead to US dependency protectionism claims to prevent.
rapport.racap.com/all-storie…
Zach Scheiner retweeted
we call it the Innovation Treadmill in the book. no other industry has to replace all its products every ~15yrs. yes that means the 10% of products that are branded at any one time are expensive to provide incentive for people to innovate, but the net result is for ~$200/month americans get a netflix like subscription to all drugs from the past, present, and future and have scientists running as hard as they can on that treadmill to stay mostly in place. a pretty darn good deal. doesn't mean there isn't also a major affordability crisis. #1 insurance doesn't act like insurance like it used to, exposing too many to those branded prices when you need those medicines. and #2 the other $1100/month of healthcare costs that don't go generic and are rising rapidly with inflation. most americans already can't sustain the insurance premiums that fund that $1100 today.
Zach Scheiner retweeted
Every year, I share this video of French caretakers who take sand from Omaha Beach in Normandy, and scrub them into the letters to give them the gold coloring.
They do this for all 9,386 US soldiers who died.
France also gave us this land as American soil. #MemorialDayWeekend
Zach Scheiner retweeted
The paradox of biotech protectionism: Why walling off China biotech weakens America
US ban on Chinese biotech/trials would return pharma leadership to Europe, slow US patient access to new meds, & lead to US dependency protectionism claims to prevent.
rapport.racap.com/all-storie…
MAHA? This is a disaster. National sabotage that will take years, maybe a decade or more, to repair.
NEW: A serious staffing shortage — of the Trump admin's own making — is delaying the agency's ability to send billions to universities around the US, leaving labs reeling.
“I thought we were at rock bottom”, a senior NIH official said. “We are below rock bottom now.”
156
Zach Scheiner retweeted
Spot on @Elijahjstacy - patients deserve simple clarity on the FDA’s true role.
FDA approval is not an endorsement that a drug is “incredible” or the best on the market. It’s like a building permit: it simply confirms the therapy meets rigorous standards for safety and efficacy.
Once that permit is granted & the drug reaches the market, FDA is only one of four layers of protection & decision-making. Patients can choose not to take it, doctors can decide not to prescribe it, and insurers can opt not to pay if it’s not right for that individual.
Taking away choice because a drug isn’t “absolutely perfect” means patients and physicians never even get the option to consider it. Putting patients first means preserving every possible tool—so families and doctors can decide together.
One thing I think would really help patient communities is a better understanding of FDA’s role.
What does FDA actually do? What does it not do? What does “approval” really mean? What does “making a drug available” actually mean?
Patients need to understand this process more clearly so we can advocate more effectively and have a better relationship with FDA. We have to know each other in order to help each other.
I’d love for someone with real regulatory/medical experience to explain this simply for my fellow patients.
This is a great resource. Simple fixes that would go a long way in increasing affordability while preserving incentives for new medicines.
Should you ever find yourself in a position to talk healthcare policy with anyone and they ask “so what are saying are the right fixes?”, NPLB put essentials in one place.
Plain, short. Solve affordability w/ 1st $ coverage; preserve incentives for R&D.
nopatientleftbehind.org/nplb…
1
150
Zach Scheiner retweeted
I move for making biotech board meetings more efficient, effective, and even joyful. Experience directors have seconded. Here’s why/how/who. (Elephant slide, CVP, BLATT, exec session upfront, etc)
And article is a Claude agent help prep pre-reads.
rapport.racap.com/all-storie…





















